IMVT
Immunovant Inc
NASDAQ: IMVT · HEALTHCARE · BIOTECHNOLOGY
$26.95
-0.15% today
Updated 2026-04-29
Market cap
$5.49B
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.67
Dividend yield
—
52W range
$13 – $30
Volume
1.4M
Immunovant Inc (IMVT) Financial statements
SEC filings — annual and quarterly data.
Balance sheet — annual
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $113170.00 | $405000.00 | $109.39M | $412.49M | $515.56M | $405.84M | $666.71M | $776.22M |
| Cash & equivalents | — | $325000.00 | $100.57M | $400.15M | $493.82M | $376.53M | $635.37M | $713.97M |
| Current assets | $113170.00 | $325000.00 | $109.08M | $409.01M | $512.93M | $404.33M | $665.77M | $767.66M |
| Total liabilities | $1.61M | $380448.00 | $15.32M | $21.01M | $45.74M | $43.34M | $48.95M | $68.78M |
| Current liabilities | $1.61M | $380448.00 | $15.32M | $18.77M | $44.52M | $43.30M | $48.61M | $68.78M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Shareholder equity | $-1.50M | $24552.00 | $94.07M | $391.48M | $469.82M | $362.49M | $617.76M | $707.45M |
| Retained earnings | — | $-448.00 | $-91.23M | $-198.66M | $-355.39M | $-566.35M | $-825.68M | $-1.24B |
| Accounts receivable | — | $2.96M | $3.04M | $1.14M | $12.86M | $885000.00 | $5.50M | $2.51M |
| Inventory | — | — | — | $0.00 | $0.00 | $0.00 | $-24.90M | — |
| Goodwill | — | — | — | — | — | — | — | — |